PAR

0.00%

26.5¢ paradigm biopharmaceuticals limited..

Thanks very informative and yes poster does state "SF" so no...

First 28 Last

Share
Profile

Follow
Denial

9,904 Posts.

1285

22/03/23

13:03

Post #: 66899145
Share

Originally posted by Zenox: ↑

DMOAD is basically "disease modifying", so if the treatment groups cluster differently to placebo and these clusters are tight then it represents a modification to the underlying disease, otherwise there's no other reason for why they would cluster differently. Of course it would need to be interpreted in conjunction with the 6 month data, which is vast and complex.

The real picture of how iPPS acts in vivo will come with the autopsy results from the canine study and cross sections of the joint area. This will allow us to see what is happening to ARGS, COMP, CTX etc in the joint. The reality is we don't know how iPPS improves pain and function scores, but we will soon find out. If we see ARGS being built up or retained, then that's disease modifying. You don't need to see a reduction of all biomarkers or the joint returned to its youthful state, that will simply never happen.

PAR doesn't know precisely how iPPS acts in vivo, hence the reason why 002 is exploratory. We have already met the primary endpoint, so all other endpoints are essentially free shots at goal. PAR have an idea of how iPPS works from previous studies, but we now need to show 1) how iPPS improves pain and function scores in vivo (for approval) and 2) whether or not iPPS halts the disease process (for the DMOAD label).

For CTX-II, IL-b and C2C, I presume either they couldn't really detect these proteins in enough of the synovial fluid samples to generate meaningful results or they were only present in very low quantities. PAR previously identified CTX-II reduced in the serum of trial participants and in the canine study, so we should expect to see it as part of the 6 month data release.

Expand

Thanks very informative and yes poster does state "SF" so no reflective of urine test results.

PAR Price at posting: $1.33 Sentiment: Buy Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

YAL

Yancoal Australia reports strong Q3 financials

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

SWP

Swoop lobs $18M offer at microcap telecom Vonex – in which it holds 19.9%

ASX Market Open: ASX set for red Friday after flat night in Wall Street | 18 Oct

TLX

Telix Pharmaceuticals' quarterly revenue exceeds AU$200M

SGR

Thousands eye Star on HotCopper, SkyCity in strife – are ASX casino stocks safe anymore?

TLG

Talga Group wins key permit for flagship graphite mine in Sweden

THB

Thunderbird picks up plethora of uranium targets based on EM survey in Canada

M4M

Macro and Norden set up transport solutions initiative for West Pilbara

TYP

Tryptamine psilocin treatment found safe in IV infusion during early stage trial

There are more pages in this discussion • 52 more messages in this thread...

First 28 Last

Add PAR (ASX) to my watchlist

(20min delay)
Last 26.5¢		Change 0.000(0.00%)		Mkt cap ! $92.81M

Open	High	Low	Value	Volume
27.0¢	29.0¢	25.5¢	$430.3K	1.585M

Buyers (Bids)

No.	Vol.	Price($)
1	5500	26.0¢

Sellers (Offers)

Price($)	Vol.	No.
26.5¢	36162	3

View Market Depth

No.	Vol.	Price($)
1	5500	0.260
3	61837	0.255
3	45200	0.250
1	15000	0.245
5	87084	0.240

Price($)	Vol.	No.
0.265	36162	3
0.270	25000	1
0.275	3350	1
0.285	46000	1
0.290	68778	4

Last trade - 16.10pm 18/10/2024 (20 minute delay)

PAR (ASX) Chart

Thanks very informative and yes poster does state "SF" so no...

Yancoal Australia reports strong Q3 financials

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Swoop lobs $18M offer at microcap telecom Vonex – in which it holds 19.9%

ASX Market Open: ASX set for red Friday after flat night in Wall Street | 18 Oct

Telix Pharmaceuticals' quarterly revenue exceeds AU$200M

Thousands eye Star on HotCopper, SkyCity in strife – are ASX casino stocks safe anymore?

Talga Group wins key permit for flagship graphite mine in Sweden

Thunderbird picks up plethora of uranium targets based on EM survey in Canada

Macro and Norden set up transport solutions initiative for West Pilbara

Tryptamine psilocin treatment found safe in IV infusion during early stage trial

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Thanks very informative and yes poster does state "SF" so no...

Top Stories

Yancoal Australia reports strong Q3 financials

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Swoop lobs $18M offer at microcap telecom Vonex – in which it holds 19.9%

ASX Market Open: ASX set for red Friday after flat night in Wall Street | 18 Oct

Telix Pharmaceuticals' quarterly revenue exceeds AU$200M

Thousands eye Star on HotCopper, SkyCity in strife – are ASX casino stocks safe anymore?

Talga Group wins key permit for flagship graphite mine in Sweden

Thunderbird picks up plethora of uranium targets based on EM survey in Canada

Macro and Norden set up transport solutions initiative for West Pilbara

Tryptamine psilocin treatment found safe in IV infusion during early stage trial

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News